ClinicalTrials.gg
Drug

Vorasidenib clinical trials

Also written AG-881 and VORANIGO.

studies test it
24
open now
8
in phase 3
4
first study started
2015

How each study uses vorasidenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the vorasidenib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
6 Aug 2024 · VORANIGO · NDA 218784 (FDA, Drugs@FDA)
European Union
17 Sept 2025 · Voranigo · EMEA/H/C/006284 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Vorasidenib
14
S095032
2
Vorasidenib 40 mg Oral Tablet
2

Brand

VORANIGO
2

Development codes

AG-881
9
AGI 23088
1
AGI 0023088
1

Studies by the year they started

22 studies that test it; most in 2025 (5); 2 more planned to start later

Studies that test vorasidenib, by start year
YearStudies
20152
20181
20194
20201
20233
20241
20255
20265

By phase

A phase 1/2 study counts in both.

Phase 1
17
Phase 2
3
Phase 3
4
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 12 · Other 12

Institut de Recherches Internationales Servier (6) · Agios Pharmaceuticals, Inc. (5) · Institut de Recherches Internationales Servier (I.R.I.S.) (4) · Servier (Tianjin) Pharmaceutical Co. LTD. (1) · Servier (1) · Servier Bio-Innovation LLC (1) · M.D. Anderson Cancer Center (1) · Megan Mantica (1)

Often tested with

Tested in the same studies.

Omeprazole (2) · Temozolomide (1) · Ivosidenib (1) · Bupropion (1) · Flurbiprofen (1) · Midazolam (1) · Repaglinide (1) · Rosuvastatin (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 3

Studies that test vorasidenib.

Studies

Open first, then newest update. How each study uses vorasidenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 24

See all 24 studies that test vorasidenib →

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call vorasidenib · ClinicalTrials.gg INT001611

  • MeSH (NLM) C000716758vorasidenibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 789Q85GA8PVORASIDENIBConfirmed FDA, NLM, Wikidata
  • Wikidata Q122240747vorasidenibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C152914VorasidenibOne source FDA
  • DrugBank DB17097One source Wikidata

Also registered as vorasidenib hemicitric acid hemihydrate (UNII X478M962XG).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.